◎ Sugi Atlas

Atlas / Drug / Follitropin

Follitropin

drug
On this page

Also known as F.s.h.-p injectableFolitropina epsilonFolitropina gammaFollicle stimulating hormoneFollitropin (pig)Follitropin alfa/betaFollitropin epsilonFollitropin gammaFollitropin porcineFollitropine epsilonFollitropine gammaFollotropin recombinantFolltropin-vFsh (menotropins)Menotropins (fsh)Super-ov

Summary

Follitropin (CHEMBL4297955) is an approved unknown (ATC G03GA10) targeting FSHR; indicated across 8 conditions including male infertility and primary ovarian failure.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Unknown
  • ATC class: G03GA10
  • Targets: 1 (FSHR)
  • Indications: 8 conditions
  • Clinical trials: 11

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4297955
NameFollitropin
TypeUnknown
Max phase4
ATCG03GA10

Also known as: F.s.h.-p injectable, Folitropina epsilon, Folitropina gamma, Follicle stimulating hormone, Follitropin, Follitropin (pig), Follitropin alfa/beta, Follitropin epsilon, Follitropin gamma, Follitropin porcine, Follitropine epsilon, Follitropine gamma

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
FSHRFSH receptorAgonist0%P23945

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): FSHR.

Top Reactome pathways

2 total, by targets touching each:

PathwayTargetsGenes
Hormone ligand-binding receptors1FSHR
G alpha (s) signalling events1FSHR

Dominant GO biological processes

GO termTargets
primary ovarian follicle growth1
regulation of systemic arterial blood pressure1
G protein-coupled receptor signaling pathway1
adenylate cyclase-activating G protein-coupled receptor signaling pathway1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway1
phospholipase C-activating G protein-coupled receptor signaling pathway1
spermatogenesis1
female gamete generation1
locomotory behavior1
gonad development1
male gonad development1
female gonad development1
hormone-mediated signaling pathway1
intracellular water homeostasis1
regulation of platelet-derived growth factor receptor signaling pathway1

Indications & clinical

Indications

8 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
male infertility4MONDO:0005372EFO:0004248
primary ovarian failure4MONDO:0005387EFO:0004266
hypogonadism4MONDO:0002146MONDO:0002146
infertility disorder3MONDO:0005047EFO:0000545
anovulation3MONDO:0002775MONDO:0002775
polycystic ovary syndrome2MONDO:0008487EFO:0000660
female infertility1MONDO:0021124EFO:0008560

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

PhaseTrials
Not specified4
PHASE32
PHASE41
PHASE21
PHASE1/PHASE21
EARLY_PHASE11
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04430621PHASE4UNKNOWNEffects of FSH on Endothelial Function (FEND)
NCT00335725PHASE3COMPLETEDEfficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.
NCT00749853PHASE3SUSPENDEDEfficacy of Ovarian Stimulation Based on FSHR Genotype Status
NCT01794208PHASE2COMPLETEDEfficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®
NCT02179255PHASE1/PHASE2UNKNOWNHuman Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF
NCT06414096PHASE1RECRUITINGUse of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
NCT03356964EARLY_PHASE1COMPLETEDStep Down FSH Approach and Late Follicular Phase in Progesterone Level
NCT00619333Not specifiedUNKNOWNInactive FSH in Galactosemia
NCT01662180Not specifiedUNKNOWNPredicting Ovarian Response in Artificial Insemination With Low Stimulation
NCT03300518Not specifiedCOMPLETEDEffectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient
NCT04854707Not specifiedCOMPLETEDAn Observational Study of Follitropin Alpha Biosimilar: the Real-world Data

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

MoleculeSourceStatusShared targets
YohimbinePubChemApprovedFSHR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot